Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Durie

Showing results (51-60 of 148) with videos related to

Pageof 15
Sort By:
American Journal of Hematology|August 18, 2020
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myelomaBrian G M Durie, Shaji K Kumar, Saad Z Usmani, et al.
Blood Cancer Journal|February 13, 2023
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myelomaSridurga Mithraprabhu, John Reynolds, Rose Turner, et al.
Leukemia Research|July 3, 2013
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma networkDaryl Tan, Kihyun Kim, Jin Seok Kim, et al.
British Journal of Haematology|July 23, 2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Lee Wolf, et al.
Leukemia|May 8, 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaM Dimopoulos, E Terpos, R L Comenzo, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Lancet (London, England)|December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialBrian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Blood|September 9, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, et al.
Leukemia|August 27, 2013
IMWG consensus on risk stratification in multiple myelomaW J Chng, A Dispenzieri, C-S Chim, et al.
Annals of Hematology|July 30, 2018
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM RegistryRafat Abonour, Lynne Wagner, Brian G M Durie, et al.
Pageof 15

Showing results (51-60 of 148) with videos related to

Sort By:
Pageof 15
American Journal of Hematology|August 18, 2020
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myelomaBrian G M Durie, Shaji K Kumar, Saad Z Usmani, et al.
Blood Cancer Journal|February 13, 2023
Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myelomaSridurga Mithraprabhu, John Reynolds, Rose Turner, et al.
Leukemia Research|July 3, 2013
The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma networkDaryl Tan, Kihyun Kim, Jin Seok Kim, et al.
British Journal of Haematology|July 23, 2009
Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myelomaSundar Jagannath, Brian G M Durie, Jeffrey Lee Wolf, et al.
Leukemia|May 8, 2009
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple MyelomaM Dimopoulos, E Terpos, R L Comenzo, et al.
British Journal of Haematology|November 19, 2009
Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myelomaWilliam I Bensinger, Sundar Jagannath, Robert Vescio, et al.
Lancet (London, England)|December 27, 2016
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialBrian G M Durie, Antje Hoering, Muneer H Abidi, et al.
Blood|September 9, 2025
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)Terri L Parker, Adam Rosenthal, Vaishali Sanchorawala, et al.
Leukemia|August 27, 2013
IMWG consensus on risk stratification in multiple myelomaW J Chng, A Dispenzieri, C-S Chim, et al.
Annals of Hematology|July 30, 2018
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM RegistryRafat Abonour, Lynne Wagner, Brian G M Durie, et al.
Pageof 15